Skip to main content
Equibles
DVA logo

DVA · Davita Inc.

Track DVA — free

Use DVA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about DVA

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$173.82 -1.42 (-0.81%) At close · Aug 21
Market Cap
$11.18B
Shares
63.80M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$173.82 Open$175.25 Day$173.74–176.19 52W close$103.87–240.96 Avg vol 30d883K Short int4.3M · 6.7% float · 7.5d Short vol76% Last earningsAug 4, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 4

Up next

Next earnings call
Nov 4, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 4, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Strong Quant / Vol High
      Market backdrop VIX 15.1 · calm Equity put/call 0.58
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg +8%
      above
      Price vs 50-day avg −19%
      below
      RSI (14) 24
      oversold
      MACD trend Negative
      52-week position 51%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Strong
      1-month return −26%
      trailing
      6-month return +13%
      trailing
      YTD return +53%
      this year
      Relative strength +1%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50d $214 › 200d $161 — 50d above 200d
      Institutional flow Accumulating
      +11% holders QoQ · +136 funds added
      Insider flow Distributing
      Net -$54.3M over 90 days · 100% sells
      Short interest Falling
      6.72% of float · ▼ -4.7% MoM · 7.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      632 holders — near 3-yr high, broad support
      Squeeze score 55
      elevated · 0–100
      Fundamentals
      Strong
      Revenue growth +6%
      Y/Y
      EPS growth −8%
      Y/Y
      Free cash flow $1.3B
      Valuation P/E 14.4
      below peers
      Buyback $1.4B
      remaining
      Balance sheet $4.0B
      net debt
      Quant / Vol
      risk profile
      High
      Volatility 45%
      annualized · 1-yr
      Max drawdown −28%
      past year
      ATR 3.8%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Aug 4, 2026
      Adjusted diluted net income per share attributable to DaVita Inc · Current 2026 guidance Non-GAAP $14.10 – $15.20
      Prior guidance period ended · from the 8-K filed Oct 29, 2025
      Adjusted diluted net income per share attributable to DaVita Inc · Current 2025 guidance $10.35 – $11.15

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Neutral
      2 · 4 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +8% Bullish
      Price vs 50-day avg
      −19% Bearish
      RSI (14)
      24 Neutral
      MACD trend
      Negative Bearish
      52-week position
      51% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 3 of 6
      Trend (MA cross) No cross
      50d $214 › 200d $161 — 50d above 200d
      Institutional flow Accumulating
      +11% holders QoQ · +136 funds added
      Insider flow Distributing
      Net -$54.3M over 90 days · 100% sells
      Short interest Falling
      6.72% of float · ▼ -4.7% MoM · 7.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      632 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $104 Now $174 · 51% Range high $241
      vs 200-day avg +8% vs 50-day avg -19%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Adjusted net income attributable to DaVita Inc. non-GAAP $463M Six months ended June 30, 2026 —
      Amount spent on share repurchases $348M Three months ended June 30, 2026 —
      Annualized aggregate risk based spend $5.8B As of June 30, 2026 —
      Annualized medical spend (risk-based IKC) $5.8B As of June 30, 2026 —
      Average patient service revenue per treatment $415.87 Three months ended June 30, 2026 —
      Consolidated EBITDA non-GAAP $3.02B Twelve months ended June 30, 2026 —
      GAAP → non-GAAP reconciliation
      GAAP Net income from continuing operations attributable to DaVita Inc. 822M
      +303M Income taxes
      +540M Interest expense
      +710M Depreciation and amortization
      +342M Net income attributable to noncontrolling interests
      +127M Stock-settled stock-based compensation
      +16M Debt extinguishment and modification costs
      +7M Expected cost savings and expense reductions
      +149M Other
      = Consolidated EBITDA 3.02B
      DSO 52 As of June 30, 2026 —
      Free cash flow, last twelve months non-GAAP $1.31B Last twelve months ended June 30, 2026 —
      General and administrative expenses per treatment $45.79 Three months ended June 30, 2026 —
      International outpatient dialysis centers 595 As of June 30, 2026 —
      Number of shares repurchased 5,243 Six months ended June 30, 2026 —
      Number of treatment days 78 Three months ended June 30, 2026 —
      Patient care costs per treatment $277.4 Three months ended June 30, 2026 —
      Patients in other integrated care arrangements 5,700 As of June 30, 2026 —
      Patients in risk-based integrated care arrangements 64,900 As of June 30, 2026 —
      Per day year-over-year change 0.6% Three months ended June 30, 2026 —
      Total outpatient dialysis centers 3,266 As of June 30, 2026 —
      Total patients 298,500 As of June 30, 2026 —
      U.S. outpatient dialysis centers 2,671 As of June 30, 2026 —
      Adjusted net income from continuing operations non-GAAP $818M Year ended December 31, 2025 —
      Adjusted operating income margin non-GAAP 15.3% Year ended December 31, 2025 —
      Average U.S. dialysis treatments per day 91,608 Q4 2025 —
      Effective income tax rate on adjusted income from continuing operations attributable to DaVita I non-GAAP 25.8% Year ended December 31, 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Medical Care Facilities — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      DVA
      Davita Inc.
      this stock
      		$11.18B +53.0% +6.5% 14.4 6.7%
      HCA
      HCA Healthcare, Inc.
      		 $95.24B -8.1% +7.1% 14.8 2.7%
      FSNUY
      Fresenius SE & Co. KGaA
      		 $30.64B -4.8% — — 0.0%
      THC
      Tenet Healthcare Corp
      		 $21.98B +41.3% +0.9% 10.5 4.0%
      FMS
      Fresenius Medical Care AG
      		 $12.49B -1.6% +5.9% — 0.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      632
      % held
      96.1%
      Net QoQ
      +2.4M sh
      Top holder
      Berkshire Hathaway Inc
      Held Float
      View
      Held by Funds
      Fund positions
      514
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      4.3M
      Days to cover
      7.5d
      Change
      -213.4K sh
      View
      Short Volume
      Short vol %
      76%
      As of
      Aug 21, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      99
      Value
      $23.9K
      As of
      Jul 30, 2026
      View
      Off-Exchange
      Off-exchange %
      38.0%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$54.3M
      Buyers / Sellers
      0 / 3
      Buyers Sellers
      View
      Congressional Trades Buy
      Member
      Alan Armstrong
      Amount
      $1.0K–$15.0K
      Traded
      Mar 27, 2026
      View
      Financials
      Financials
      Revenue (FY)
      $13.6B
      Net income (FY)
      $746.8M
      EPS diluted
      $9.84
      View
      Buybacks
      Authorized
      $2.0B
      Remaining
      $1.4B
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 4, 2026
      This year
      8
      View
      Proposed Sales
      Value
      $8.2M
      Shares
      39.4K
      Filed
      Jun 16, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 4, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      DVA -3.5% -26.2% +12.9% -27.6% +53.0%
      SPY -1.4% +3.6% +11.6% +2.5% +12.3%
      vs SPY -2.1% -29.8% +1.3% -30.1% +40.7%

      Capital returns

      Buyback program · as of Jul 31, 2026
      Authorized
      $2.00B
      Spent (derived)
      $627.04M
      Remaining
      $1.37B
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 927066 CUSIP 23918K108 13F (30d) 567 filings 538 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)